rs1401417
This is a regulatory region variant variant in the CRY2 gene.
▶Research that mentions this SNP (1)
▶Circadian genes and risk of prostate cancer in the prostate cancer prevention trialAssociationN=2,181Lisa W. Chu et al.(2018)· Molecular Carcinogenesis
A nested case-control study of 1,092 prostate cancer cases and 1,089 controls from the Prostate Cancer Prevention Trial examined 240 SNPs in 9 circadian genes. The study found suggestive associations between NPAS2 variants and prostate cancer risk in finasteride-treated men, with rs746924 remaining significant after Bonferroni correction (OR=1.5, p=9.6×10⁻⁵). In placebo-treated men, no significant associations with circadian gene variants were detected, suggesting potential modification of genetic effects by treatment with the androgen-reducing drug finasteride.
About CRY2
This gene encodes a flavin adenine dinucleotide-binding protein that is a key component of the circadian core oscillator complex, which regulates the circadian clock. This gene is upregulated by CLOCK/ARNTL heterodimers but then represses this upregulation in a feedback loop using PER/CRY heterodimers to interact with CLOCK/ARNTL. Polymorphisms in this gene have been associated with altered sleep patterns. The encoded protein is widely conserved across plants and animals. Two transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Feb 2014]
View all CRY2 variants →Gene information from NCBI Gene. Variant classifications from ClinVar.
Community Wiki
No community notes yet for this variant. Sign in to start one.
Comments
Sign in to join the discussion.
Loading comments…